Last updated on June 2020

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Brief description of study

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for up to 17 cycles. Participants who receive placebo or who stop treatment after receiving 17 cycles of pembrolizumab in Part 1, do not experience disease recurrence within 6 months of completing pembrolizumab in Part 1, and do not stop treatment with pembrolizumab for disease recurrence or intolerability, may be eligible to receive up to 35 additional cycles of pembrolizumab in Part 2 in an open-label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo.

Clinical Study Identifier: NCT03553836

Find a site near you

Start Over

Yale University ( Site 0035)

New Haven, CT United States
  Connect »

Mayo Clinic Florida ( Site 0024)

Jacksonville, FL United States
  Connect »

MPOC ( Site 0803)

Pretoria, South Africa
  Connect »

Cancercare ( Site 0810)

Cape Town, South Africa
  Connect »